Gossamer Bio's consensus analyst price target has recently risen from $8.86 to $9.50, which signals a more optimistic outlook among market observers. This adjustment comes as analyst sentiment grows ...

Investing.com - Cantor Fitzgerald has maintained its Overweight rating on Gossamer Bio Inc. (NASDAQ:GOSS) as the company’s seralutinib clinical trial approaches a significant milestone. The stock, ...

This Thanksgiving, instead of turkeys, think of ducks — and “wascally wabbits,” as MeTV Toons airs over 12 full hours of classic Looney Tunes featuring Daffy Duck and Bugs Bunny as part of their ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20251105312270/en/ The articles, information, and content displayed on this webpage ...

SAN DIEGO, November 05, 2025--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Gossamer Bio Inc. (GOSS) on Wednesday reported a loss of $48.2 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of ...